Phase III trial to assess the efficacy and safety of EscharEx® for debridement and facilitation of active wound closure Interim analysis planned after 65% of patients complete treatment, expected in ...

Garner is a behavioral intervention scientist and an assistant professor of nutritional sciences.

Nasdaq’s determination is based on the Company meeting all other applicable requirements for listing on the Nasdaq Capital Market, with the exception of the bid price requirement, and the Company’s ...

Strong enrollment activity to start 2025146 patients enrolledTORONTO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or ...

FDA Approves First New Non-Opioid Pain Pill in Decades By India Edwards HealthDay Reporter FRIDAY, Jan. 31, 2025 (HealthDay News) -- The U.S. Food and Drug Administration (FDA) has approved ...

Shares of Vertex Pharmaceuticals Inc. surged ahead of Friday’s market open after the Food and Drug Administration approved the company’s non-opioid pain treatment. It’s the first new class ...

For the first time in two decades, the Food and Drug Administration (FDA) has approved a new class of medication that provides an alternative to addictive opioids for patients looking to manage ...

Vertex has attracted interest from Wall Street for its ambitious drug pipeline that involves winning FDA approval for multiple drugs across several forms of chronic pain, which generally represents a ...

Vertex has attracted interest from Wall Street for its ambitious drug pipeline that involves winning FDA approval for multiple drugs across several forms of chronic pain, which generally ...

FDA approval of PATHWAY HER2 (4B5) test expands diagnostic capabilities for HER2-ultralow metastatic breast cancer, enabling targeted treatment with trastuzumab deruxtecan. HER2-ultralow ...

(CNN) – The U.S. Food and Drug Administration approved the first new type of pain medication in more than two decades, and it’s not an opioid. The drug is suzetrigine under the brand name Journavx. It ...